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US guidelines recommend that most women older than 65 years cease cervical screening after two consecutive negative
cotests (concurrent HPV and cytology tests) in the previous 10 years, with one in the last 5 years. However, this
recommendation was based on expert opinion and modeling rather than empirical data on cancer risk. We therefore estimated
the 5-year risks of cervical precancer (cervical intraepithelial neoplasia grade 3 or adenocarcinoma in situ [CIN3]) after one, two
and three negative cotests among 346,760 women aged 55–64 years undergoing routine cotesting at Kaiser Permanente
Northern California (2003–2015). Women with a history of excisional treatment or CIN2+ were excluded. No woman with one or
more negative cotests was diagnosed with cancer during follow-up. Five-year risks of CIN3 after one, two, and three
consecutive negative cotests were 0.034% (95% CI: 0.023%–0.046%), 0.041% (95% CI: 0.007%–0.076%) and 0.016%
(95% CI: 0.000%–0.052%), respectively (ptrend < 0.001). These risks did not appreciably differ by a positive cotest result prior
to the one, two or three negative cotest(s). Since CIN3 risks after one or more negative cotests were significantly below a
proposed 0.12% CIN3+ risk threshold for a 5-year screening interval, a longer screening interval in these women is justified.
However, the choice of how many negative cotests provide sufficient safety against invasive cancer over a woman’s remaining
life represents a value judgment based on the harms versus benefits of continued screening. Ideally, this guideline should be
informed by longer-term follow-up given that exiting is a long-term decision.
Background
Cervical screening is widely acknowledged to be extremely
effective at preventing cervical cancer. Current United States
(US) and European screening guidelines are based on strong
scientific evidence for who should be eligible for screening,
which screening test to use (cytology and/or HPV tests), how
to manage abnormal screening results and the appropriate
length of screening intervals.1–10 However, there is very little
evidence available on the appropriate upper age limit to exit
women from routine screening. Among countries with
established screening programs, the upper age limit for cervical
screening is inconsistent, varying from age 60 years in Finland,
the Netherlands and Ireland11,12 to age 69 years and older in
Australia, Japan, Norway and Uruguay.11,13–15
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Until recently, some of the screening recommendations in
the US did not have an upper age limit,16 and cervical screening
over age 65 years was common. In 2012, the US cervical screen-
ing guidelines were revamped, recommending concurrent HPV
and cytology testing (known as cotesting) every 5 years or cytol-
ogy testing every 3 years for women aged 21–65 years.17 These
guidelines recommended that women exit routine cervical
screening at age >65 years if they have at least three consecutive
negative cytology tests or two negative cotests since age 55 years,
with no CIN2+ (cervical intraepithelial neoplasia grade 2 or
worse) in the last 20 years, and that the most recent screen
occurred within the past 5 years. The 2018 recommendation
statement for the US Preventive Services Task Force (USPSTF)
cervical screening guidelines maintained the 2012 guidelines for
women exiting cervical screening.18 In practice, with a 5-year
interval for cotesting, as in the 2018 recommendations, a
woman’s last screening test could occur 5 years prior to the rec-
ommended exiting age.
However, recommendations for exiting criteria are based
only on expert opinion and mathematical modeling because of
the lack of empirical data. The US consensus recommendation
was labeled as “weak” due to the lack of empirical data,17 and
the choice of age 65 years to cease screening was acknowledged
to be based solely on expert opinion. This led to a call for pro-
spective studies in older women as a key research priority.17
Furthermore, there is no empirical evidence underlying the
requirement for two negative cotests, with no reported data on
the risk of precancerous lesions or cancer after two negative
cotests compared to risks after one or three negative cotests
among women who would be eligible to exit screening.
Data from Kaiser Permanente Northern California (KPNC)
represents the largest and longest experience with cotesting in
the world. KPNC clinical guidelines differ slightly from the
national guidelines given above. Although national guidelines
currently recommend cotesting every 5 years, KPNC has rec-
ommended cotesting every 3 years since its introduction in
2003. The updated 2012 consensus guidelines for the manage-
ment of abnormal screening tests recommended a 3-year screen-
ing interval after an HPV-negative atypical squamous cells of
undetermined significance (ASCUS) cotest result.19 The 2013
KPNC clinical guidelines also recommend a woman with an
HPV-negative ASCUS cotest result should have their next
screen 3 years later, although in KPNC this corresponds to a
return to routine screening.19 The updated 2012 consensus
guidelines explicitly state that a woman should not be exited
from screening with an HPV-negative ASCUS result.19 Since
2014, KPNC guidelines have recommended exiting women aged
66 years and older whose most recent cotest since age 55 years
was negative, or who had three negative cytology tests at least a
year apart since age 55 years, provided they did not have prior
CIN2+.20
We calculate short-term (3- and 5-year) risks of cervical intra-
epithelial neoplasia (CIN) grade 3 and adenocarcinoma in situ
(AIS) (CIN3) as well as CIN grade 2, CIN3 and AIS (CIN2+)
after one, two and three negative cotests among 346,760 women
aged 55–64 years; no woman was diagnosed with cancer after
one or more negative cotests in this subcohort. These estimates
of short-term risks provide information on how much precancer
would be present if a further screening test were to occur at the
same interval. We also calculate the frequency of abnormal
screening test results after negative cotests.
Methods
We analyzed prospectively collected data from women whose
healthcare was provided by Kaiser Permanente Northern
California (KPNC). The dataset contains all cervical screening
tests (both HPV and cytology) and results which took place
between January 1, 2003, and December 31, 2015, as well as col-
poscopy and biopsy data between these dates. Across all ages,
there are over 1.4 million women with at least one record in this
dataset. The cohort has been described in detail previously.21
The KPNC Institutional Review Board approved use of the data,
and the National Institutes of Health Office of Human Subjects
Research deemed this study exempt from IRB review.
Our inclusion and exclusion criteria were as follows. We
identified women aged 55–64 years who had at least one nega-
tive cotest, with at least one subsequent screen. For this analysis,
we considered HPV-negative ASCUS as a positive cotest, in line
with the updated 2012 consensus guidelines.19 As women who
had negative cotests close together may have been on more
intensive follow-up due to an earlier abnormal result which we
do not have a record of, when identifying women who had two
and three consecutive negative cotests, we restricted this to nega-
tive cotests which were at least 18 months apart. We defined the
date of the nth consecutive negative cotest as Tn. Although
women whose second consecutive negative cotest was before age
60 years would not be eligible to be exited according to national
guidelines, we believe that the results from women with two
negative cotests aged 55–59 years would be a good approxima-
tion for women aged 60–64 years. Women with stand-alone
cytology or HPV tests between the two or three negative cotests
were excluded from the analyses. In addition, we excluded
What’s new?
US guidelines recommend that women older than 65 years cease screening for cervical cancer following two consecutive negative
cotests (HPV and cytology) in the previous ten years. However, these guidelines are based on modelling and expert opinion,
rather than empirical data. In this large epidemiological study, the authors estimated the risks of cervical precancer following
one, two, or three negative cotests among women aged 55-64 years. They caution that the optimal time for women to exit
screening represents a value judgment, based on the harms versus benefits of continued screening. Further data are needed.
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cotests taken within a week of a biopsy, as these were unlikely to
be screening tests. We excluded all screening or colposcopy data
after a hysterectomy or excisional treatment, as well as women
diagnosed with CIN2+ prior to the interval of interest.
We categorized the data according to screening rounds, in
order to determine what disease was diagnosed as a result of
performing one additional round of screening. We defined a
screening round to continue until a woman was no longer rec-
ommended to have more intensive follow-up due to an earlier
abnormal result, according to the 2012 consensus guidelines for
the management of abnormal cervical cancer screening tests and
cancer precursors.19 Details on how a screening round was
defined can be seen in Supporting Information Material 1.
It is important to evaluate the harms as well as the benefits
of screening. Since the number of colposcopies is often con-
sidered as a surrogate of the main harms (overtreatment and
complications) of screening older women,17 we tabulated the
number and proportion of women whose screening results
should lead to a colposcopy referral (two consecutive HPV-
positive tests, any high-grade cytology [cancer, high-grade
squamous intraepithelial lesion (HSIL), atypical squamous
cells cannot rule out HSIL (ASC-H) or atypical glandular cells
(AGC)], an HPV-positive ASCUS or low-grade squamous
intraepithelial lesion [LSIL] cotest, or two consecutive ASCUS
or LSIL cytology tests), as well as the number and proportion
of women known to have attended colposcopy in the screen-
ing round after Tn, and the number and proportion diagnosed
with CIN3 and CIN2+. We considered CIN3 to be the best
proxy for cervical cancer risk, however, CIN2 has historically
been treated. We therefore also present results for CIN2+ risk.
Additionally, when the number of CIN3 diagnoses was very
low, we used CIN2+ as the outcome. To see whether there
were clinically significant differences in these risks, which
would lead us to draw different conclusions based on these
variables, we also tabulated these results by age at Tn (55–
59 years, 60–64 years; when considering one or two consecu-
tive negative cotests [very few women have three negative
cotests aged 55–59 years]), the time between the last two neg-
ative cotests (1.5–2.5 years, 2.5–3.5 years and 3.5+ years, when
considering two or three consecutive negative cotests), and the
time between Tn and the following screening test (<1.5 years,
1.5–2.5 years, 2.5–3.5 years and 3.5+ years).
Statistical methods
Since we do not know exactly when screen-detected disease
occurred, only the date at which it was diagnosed, we considered
the date at which disease became detectable to be “interval cen-
sored”; that is, we know that it occurred between two dates. To
estimate the absolute risk of CIN3 and CIN2+ after one, two
and three negative cotests, we used the Turnbull algorithm,22 a
nonparametric method of analysis for interval-censored data.
We assumed that all disease diagnosed after Tn was not present
at Tn. Ninety-five percent confidence intervals (95% CI) for
the Turnbull absolute risk estimates were estimated through
bootstrapping, using 1000 bootstrap resamples. We considered
the start of the interval in which disease could have occurred
(i.e., the last time we are confident that disease was not present)
to be the latest date of (i) a second (or subsequent) consecutive
negative cotest, or (ii) a third (or subsequent) consecutive nega-
tive cytology or cotest prior to diagnosis, and the end of the
interval to be the date of the biopsy which resulted in a diagno-
sis. Women without a diagnosis contributed data to the risk esti-
mates after n negative cotests provided they had at least one
screening test after the nth negative cotest. These women were
right-censored (i.e., had no upper bound on when they devel-
oped disease). When considering risks after two or three nega-
tive cotests, the start of the interval was the latest date at which a
second consecutive negative cotest or third consecutive negative
cytology/cotest occurred. When considering risks after a single
negative cotest, the start of the interval was the latest date at
which a single negative cotest occurred, or a negative cytology
test after a negative cotest. A test for trend was carried out, using
a weighted generalized linear model. We additionally estimated
the 3- and 5-year risks of CIN3 and CIN2+ after a negative cotest
which followed a positive cotest (both including and excluding
HPV-negative ASCUS as a positive cotest), when both screens
were taken at ages 55–64 years. We present absolute risks, since
it is the absolute risk of future disease which is important when
considering exiting women from cervical screening.
Women whose last recorded screening result was an unre-
solved positive result (i.e., a positive screening result, which
should have led to a colposcopy referral or more intensive
screening, and had not yet returned to routine screening) are
at higher risk of CIN2+ than women whose last recorded result
was negative, though in the analyses described above both were
right-censored and treated in the same way. We therefore
present results with and without adjustment for unresolved
positive screening results. Details of the adjustment are in
Supporting Information Material 2.
Since current US screening guidelines recommend exiting
after two negative cotests, regardless of previous screening
results, we examined how the risk of CIN2+ being diagnosed
during the screening round after one, two and three consecu-
tive negative cotests was influenced by the previous screening
test result. We tabulated the following screening test result,
stratified by the preceding screening test result, even if the pre-
ceding test was taken before age 55 years. We split the result of
the screening test preceding the negative cotest(s) by all combi-
nations of HPV (negative, positive or not available) and cytol-
ogy (negative for intraepithelial lesions or malignancy [NILM],
ASCUS, LSIL, high-grade or not available) results. For strati-
fied analyses in which there were insufficient numbers of CIN3
diagnoses, CIN2+ was used as the primary outcome.
Analyses were carried out in Stata v1423 and R v3.5.24
Results
There were 346,760 women aged 55–64 years with at least one
screening or biopsy record. After exclusions, 174,205 women had
Landy et al. 3
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a single negative cotest with at least a single screening test after this
cotest; the corresponding numbers for women with two and three
consecutive negative cotests were 63,813 and 10,549, respectively.
The proportion of women with an unresolved positive screening
result was similar after one (1.2%), two (1.3%) and three (1.4%)
negative cotests. The majority of women were aged 55–59 years at
their first negative test (78.0%) and 60–64 years at their second
(62.1%) and third (97.2%) negative cotest (Table 1). Most women
with two negative cotests had 2.5–3.5 years between their negative
cotests (70.9%), and 69.8% of women with three negative cotests
had 2.3–3.5 years between their second and third negative cotests.
Median lengths of total follow-up after one, two and three negative
cotests were 3.8 years (IQR 3.0–6.1 years, maximum 12.4 years),
3.1 years (IQR 3.0–3.8 years, maximum 10.6 years) and 3.0 years
(IQR 2.6–3.2 years, maximum 8.6 years), respectively.
Risks of having an abnormal screening result after one, two
and three negative cotests were 3.2, 2.5 and 2.3%, respectively
(Table 2), with 2.1, 1.6 and 1.4% of women having abnormal
cytology, and 1.8, 1.5 and 1.3% testing HPV positive. The same
proportion of women had high-grade cytology after one, two
and three negative cotests (0.2%). The proportion of negative
cotests was very similar for women whose second negative
cotest was at age 55–59 years (97.4%) and 60–64 years (97.5%),
as was the proportion of positive HPV tests (1.5% in each age
group; data not shown).
We present the proportion of women diagnosed with CIN3
and CIN2+ in the following screening round, and absolute
risks of CIN3 and CIN2+ at 3 and 5 years with adjustment for
unresolved positive screening results as the primary results; the
crude results without this adjustment are shown in Supporting
Information Tables S1 and S2.
Overall, 1.34, 1.03 and 0.92% of women would have qualified
for referral to colposcopy based on their screening results after
one, two and three negative cotests. With adjustment for unre-
solved positive screening results, 0.027% (1 in 3,963), 0.009%
(1 in 10,998) and 0.025% (1 in 3,956) of women were diagnosed
with CIN3 in the screening round after one, two and three
negative cotests aged 55–64 years (Table 1). The corresponding
percentages for CIN2+ were 0.085% (1 in 1,170), 0.044% (1 in
2,248) and 0.025% (1 in 3,956) of women, respectively. No
women were diagnosed with cancer for the duration of follow-
up available. The adjustment for unresolved positive screening
results had a large impact on risks after three consecutive nega-
tive cotests; there was a relative increase of 167%, heavily
influenced by five women with unresolved high-grade cytology
on their screening test after three negative cotests. Using only
observed data, without adjustment for unresolved positive
screening results, 69, 170 and 89 women attended colposcopy
per CIN3 diagnosed and 22, 32 and 89 per CIN2+ diagnosed
after one, two and three negative cotests, respectively.
Absolute risks
Table 3 shows the absolute risks of CIN3 and CIN2+ at 3 and
5 years after one, two and three negative cotests. Three- and
five-year risks of CIN3 after one negative cotest were 0.025%
(95% CI: 0.014–0.036%; 1 CIN3 in 4,000 women) and 0.034%
(95% CI: 0.023–0.046%; 1 CIN3 in 1,941 women), respectively.
By comparison, 3- and 5-year risks of CIN3 after two negative
cotests were 0.010% (95% CI: 0.000–0.025%; 1 in 10,296) and
0.041% (95% CI: 0.007–0.076%; 1 in 2,420), respectively.
Three- and 5-year risks of CIN3 after three negative cotests
were both 0.016% (95% CI: 0.000–0.052%; 1 in 6,250).
There was a significant negative trend in 5-year CIN3 risk
with increasing numbers of negative cotests (p < 0.001). When
stratifying risks after one and two negative cotests by the age of
the first/second negative cotest, risks were generally slightly
higher for the older women (Supporting Information Table S3).
Similar patterns were observed for risks of CIN2+.
Table 4 shows 3- and 5-year risks after a positive cotest
(including [n = 6,365] and excluding [n = 3,456] HPV-negative
ASCUS as a positive cotest) after a negative cotest. The 5-year
CIN3 risks were 0.019% (95% CI: 0.000–0.056%) and 0.038%
(95% CI: 0.000–0.108%), respectively. The 5-year risk of CIN3
including HPV-negative ASCUS as a positive cotest was signifi-
cantly lower (p < 0.001) than after two negative cotests (0.041%,
95% CI: 0.007–0.076%), and there was no significant difference
(p = 0.682) when HPV-negative ASCUS was not considered to
be a positive cotest.
Comparing risks after one, two and three negative cotests
by the screening result prior to the negative cotests
The result of the previous screening test made a greater difference
after one negative cotest than after two or three negative cotests
(Table 5); women who had tested HPV positive at the previous
screen were much more likely to be diagnosed with CIN2+ after
a single negative cotest than women who tested HPV negative
(0.519% vs. 0.060%, p < 0.01). Similarly, women who had abnor-
mal cytology were more likely to be diagnosed with CIN2+ in the
screening round after one negative cotest than women with nega-
tive cytology (0.255% vs. 0.070%, p < 0.01). After two negative
cotests, women who had previously tested HPV positive were
more likely to have CIN2+ diagnosed than women who had not,
though this difference was not statistically significant (0.168% vs.
0.054%, p = 0.25). Women who had abnormal cytology had a
slightly higher, though nonsignificant, risk of being diagnosed
with CIN2+ compared to women with negative cytology (0.081%
vs. 0.042%, p = 0.52). Compared to women who were HPV nega-
tive with abnormal cytology at the previous screening round,
women who tested HPV-positive, cytology-negative had a non-
significantly higher risk of CIN2+ (0.206% vs. 0.100%, p = 0.60).
Only one woman was diagnosed with CIN2+ (in fact CIN3) after
three negative cotests; her antecedent cotest was negative
(i.e., four consecutive negative cotests).
Discussion
There has been no empirical evidence on which to base exiting
guidelines for cervical cancer in the era of HPV testing. In this
article, we provide evidence on the absolute risks of CIN3
4 Absolute risks of cervical precancer
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among women eligible for exiting in the era of cotesting. We
have shown that the 5-year absolute risk of CIN3 after two nega-
tive cotests among women aged 55–64 years is less than 1 in
2400, far less than the risk after annual cytology tests, which has
been proposed as the risk threshold for 5-year return (0.12%
[1 in 862] in unpublished KPNC data).25 The decision to dis-
continue cervical screening and at what age and risk is a societal
one; Swedish guidelines require a single negative HPV test at
age 64 years or older,26 and Australian guidelines require a sin-
gle negative HPV test at age 70–74 years.27 Still, it must be rec-
ognized that it is impractical and very cost ineffective to achieve
zero lifetime risk of cervical cancer, even if women have been
previously vaccinated against HPV.28 However, these results
suggest that, at a minimum, a longer screening interval may be
appropriate for these low-risk, older women.
If we consider only the 5-year risk, then under the principle
of “equal management of equal risk,”1 we would not screen
these women 5 years after even a single negative cotest at age
55–64 years. While 5-year risk is very low, a woman should only
be exited from screening when she is considered to be at suffi-
ciently low risk of cancer for the rest of her life that the harms of
further screening outweigh the cancer-prevention benefits of
continuing to screen. However, there has not been sufficient
time since the introduction of cotesting to observe long-term
risks of cervical cancer for women exited with negative cotests
or HPV tests. To create consistent screening guidelines, ideally
an explicit maximum tolerable lifetime cancer risk threshold at
which a woman would be exited from cervical screening would
be defined. Empirical data would inform the age and screening
history that achieves a risk that is less than that threshold.
The most appropriate outcome for determining exiting
criteria is the lifetime risk of frank invasive cervical cancer.
Asymptomatic lesions such as CIN2 or CIN3, or even early
stage asymptomatic cancers, are not a concern if they do not
affect a woman’s quality of life or life expectancy. No women
in our study were diagnosed with cervical cancer. However,
since cancer is so rare, and when precancerous lesions are
treated, it is often necessary to use precancerous lesions as the
outcome to ensure sufficient power.
There is an ongoing debate over the effectiveness of screening
in older women.29,30 If screening tests or colposcopy were ineffec-
tive at screening older women, there would be no advantage to
extending the exiting criteria to an older age, even if disease preva-
lence was sufficiently high to warrant population-level screening.
Although the focus of cervical screening is to detect and treat pre-
cancerous lesions, it also detects cancers at earlier stages. Since can-
cers in older women are diagnosed at more advanced stages31 and
around 20% of cancers diagnosed aged 65 years or older are in
women who exited screening according to guidelines,32,33 there
could be an advantage of continuing screening to improve the stage
distribution (downstage) in cancers among women aged 65 years
and older and thereby reduce their morbidity and mortality.
Although there was a statistically significant negative trend
in 5-year CIN3 risk with increasing numbers of negativeTa
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cotests, the sample size was large and the absolute risk differ-
ences may not be clinically significant. It is important to con-
sider harms as well as benefits of screening. A surrogate for
the harm of screening older women is the number of col-
poscopies performed; over 1% of women attended colposcopy
in the screening round after two negative cotests, representing
32 colposcopy visits per woman diagnosed with CIN2+. This
compares to 22 and 89 colposcopy visits per CIN2+ diagnosed
after one and three negative cotests.
It is possible that the birth-cohort of women currently
approaching age 65 years have different risks of cervical cancer
to women 10 years older.34 For example, the incidence of sexu-
ally transmitted gonorrhea peaked in 1975, when women cur-
rently aged 60–64 years were aged 18–22 years.35 Thus, it is
likely that exposure to HPV, a sexually transmitted infection,
was also higher in these women compared to women from older
birth cohorts. However, if it is reasonable to assume that risks of
women exiting over the next 10 years are similar to risks in the
birth-cohort of women who have fulfilled the exiting criteria in
the past few years, we at least can use past data to evaluate
short-term risks for women who meet the exiting criteria. It is
unlikely that there will be empirical data on the lifetime cancer
risk of women being exited at the time the exiting decision is
being made. Despite this, further evaluation of the data when
more follow-up time has accrued will enable longer-term risk
estimates to be calculated, and the analysis of women born a few
years later once they have also met the exiting criteria will allow
us to identify how these risks are changing with time. It is
Table 5. The number of women who had each cotest result prior to one, two and three negative cotests, and the number and percentage of
women diagnosed with CIN2+ by the prior cotest result
Cytology result
at test preceding
one negative
cotest
n CIN2+ (n) CIN2+ (%)
HPV result at test preceding one negative cotest
HPV
negative N/a*
HPV
positive Total
HPV
negative N/a*
HPV
positive Total
HPV
negative N/a*
HPV
positive Total
NILM 58,166 22,035 799 81,000 33 19 5 57 0.057 0.086 0.626 0.070
N/a* 1,431 – 5 1,436 2 – 0 2 0.140 0.000 0.139
ASCUS 274 106 372 752 0 0 2 2 0.000 0.000 0.538 0.266
LSIL 74 8 125 207 1 0 0 1 1.351 0.000 0.000 0.483
High-grade 159 9 49 217 0 0 0 0 0.000 0.000 0.000 0.000
Total 60,104 22,158 1,350 83,612 36 19 7 62 0.060 0.086 0.519 0.074
ASCUS+ 507 123 546 1,176 1 0 2 3 0.197 0.000 0.366 0.255
Cytology result
at test preceding
two negative
cotests
HPV result at test preceding two negative cotests
HPV
negative N/a*
HPV
positive Total
HPV
negative N/a*
HPV
positive Total
HPV
negative N/a*
HPV
positive Total
NILM 18,858 9,210 486 28,554 9 2 1 12 0.048 0.022 0.206 0.042
N/a* 597 – 12 609 1 0 1 0.168 0.000 0.164
ASCUS 925 121 75 1,121 1 0 0 1 0.108 0.000 0.000 0.089
LSIL 35 11 16 62 0 0 0 0 0.000 0.000 0.000 0.000
High-grade 37 3 7 47 0 0 0 0 0.000 0.000 0.000 0.000
Total 20,452 9,345 596 30,393 11 2 1 14 0.054 0.021 0.168 0.046
ASCUS+ 997 135 98 1,230 1 0 0 1 0.100 0.000 0.000 0.081
Cytology result
at test preceding
three negative
cotests
HPV result at test preceding three negative cotests
HPV
negative N/a*
HPV
positive Total
HPV
negative N/a*
HPV
positive Total
HPV
negative N/a*
HPV
positive Total
NILM 2,434 2011 69 4,514 1 0 0 1 0.041 0.000 0.000 0.022
N/a* 58 2 60 0 0 0 0.000 0.000 0.000
ASCUS 89 27 2 118 0 0 0 0 0.000 0.000 0.000 0.000
LSIL 3 1 1 5 0 0 0 0 0.000 0.000 0.000 0.000
High-grade 6 0 0 6 0 0 0 0 0.000 0.000
Total 2,590 2039 74 4,703 1 0 0 1 0.039 0.000 0.000 0.021
ASCUS+ 98 28 3 129 0 0 0 0 0.000 0.000 0.000 0.000
Abbreviations: NILM, negative for intraepithelial lesions or malignancy; ASCUS, atypical squamous cells of undetermined significance; LSIL, low-grade
squamous intraepithelial lesion.
*This test was not carried out.
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important to regularly review risks among women who have
met the exiting criteria, so any cohorts at an increased risk can
be identified swiftly, and if appropriate, offered additional
screening.32 Future work could also consider whether it would
be sensible to offer the exiting screening test at a fixed age
(e.g., 65 years), rather than after a set interval.
There are limitations when using observed clinical practice
data to estimate absolute risks. Since women must attend col-
poscopy to be diagnosed with CIN2 or CIN3, which are asymp-
tomatic, restricting the analyses to women with a diagnosis of
CIN2+ will likely underestimate the absolute risk, due to women
with positive screening results not attending colposcopy, despite
their (relatively) high risk of CIN2+. While the proportion of
women in the study with an unresolved positive screen was low
(1.2–1.4%), when considering that only 2.5% of women had an
abnormal screening result in the screening round after two neg-
ative cotests, a large proportion of the women at highest risk of
CIN2+ have not had their disease status verified or been ret-
urned to routine screening. This leads to underestimation of the
true risk. While we have adjusted for this in the majority of the
analyses, the true risks are unknown. We have assumed that the
underlying disease status of women with unresolved positive
screening tests was missing at random,36 given their positive
screening result (i.e., that they are the same as women who had
the same positive screening result, that was resolved). We were
not able to adjust for this when stratifying the risk of CIN2+ by
the screening result prior to the negative cotest(s), due to small
numbers within each cell.
We do not know why each screening test was taken. This
is particularly relevant for screens that took place after a
woman had fulfilled the exiting criteria. In theory, women
who had fulfilled the exiting criteria would not have any more
screening tests, and would therefore not contribute any data
to our study unless they had symptomatic testing. These
women may be at higher risk than women who fulfilled the
exiting criteria and had no subsequent tests, therefore not
contributing data to our analyses.
Although there were over 170,000 women with a screening
test after a single negative cotest, only 10,000 women had a
screening test after three negative cotests, of whom only one
woman was diagnosed with CIN2+ (in fact CIN3, 2.1 years
after the third negative cotest). There were also limited follow-
up data available for the women who had three negative
cotests, as the women needed to have at least four rounds of
screening, which are recommended to take place 3 years apart,
and only follow-up after the third negative cotest is considered
among these women. We therefore only provide risk estimates
at 3- and 5-years, whereas it may be appropriate for a final
screening test to take place after a longer interval. There was
no additional information on CIN2+ risk after two negative
cotests in the screening result prior to the negative cotests,
implying that there is no benefit of using screening results
from more than the two previous screening rounds when
deciding whether to exit a woman.
The results presented here are from a single US Integrated
Health System; one which recommends four-quadrant biopsies
as standard. Thus, the sensitivity of colposcopy is likely to be
higher than in other screening programs. As we focus on out-
comes in a complete screening round after two negative cotests,
the sensitivity of colposcopy may change the amount of disease
found initially, however since women with a negative colposcopy
are recommended to attend further screening at 12 months
(which is considered to be part of the same screening round), we
assume that (even in settings with less sensitive colposcopy) a
second colposcopy would identify the majority of any disease
that was missed at the initial colposcopy. We also note that this
estimate applies to a low-risk cohort; these women have private
health insurance and have been offered three-yearly cotesting
since 2003, and have no record of a previous CIN2+ diagnosis
or excisional treatment. Although they were excluded from our
study, as they are not eligible to be exited, no one in KPNC was
diagnosed with CIN2+ after one, two or three negative cotests
which occurred after their first treatment, though numbers were
small (1,146, 410 and 109 women with one, two and three nega-
tive cotests aged 55 years and older after treatment, respectively).
No exiting criteria can guarantee absolute safety against
cervical cancer. However, it is also not reasonable or feasible
to keep women in the screening program when their risk of
future disease is too low. We have shown that the 5-year risks
of CIN3 after one, two and three negative cotests aged
55–64 years are all very low in this cohort, implying that at a
minimum, a longer screening interval is appropriate. Even
with longer follow-up and an explicit maximum tolerable life-
time cancer risk, no exiting guideline will be 100% safe. The
lack of certainty underlying the exiting criteria should be
acknowledged in the guidelines.
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